Komen's Rejection of Porn Donation is an Obscenity

Earlier this month fundraising behemoth Susan G. Komen for the Cure flatly rejected a cash donation from one of the largest online porn sites, Pornhub.com. They went so far as to insist that Pornhub stop referring to them in the press.

Their hardline decision to reject Pornhub's offer, which is to donate one cent for every 30 views of breast-related videos on their site through October 31, amounts to yet another sad little misguided political decision by the Puritanical, conservative and elitist forces within that increasingly irrelevant organization.

As I write this, Pornhub's breast-related video watch count is at 40,153,747.

Yes, 40 million.

In the time it took me to write this much, it has already jumped over 4,400 views to 40,158,201. That's $13,386 that Komen doesn't want.

Everyone is Watching

Ladies, your spouses are watching clips at Pornhub.com. Gentlemen, your spouses are watching clips at Pornhub.

How do I know? The real question is, how can't they be? For their fundraiser, Pornhub is only counting views from two categories: 'Big Tits' and 'Small Tits.' And the count is over 40 million.

Yet they have more than 60 different video categories. Yesterday 1.49% of all Internet users across the globe visited Pornhub.

Web information site Alexa.com ranks web sites according to traffic. Look at the company this web site keeps:

#65. AOL
#66. Adobe Systems
#67. ESPN
#68. Pornhub
#69. eBay International
#70. CNN

Some critics think Pornhub is doing this for the publicity. Breaking news: A site that busy doesn't need it.

This is a sincere, if gimmicky (name a fundraiser that isn't gimmicky), attempt by Pornhub to raise money and awareness for the fight against breast cancer. That's all. Just trying to do their part.

It's not like Pornhub can be linked to breast cancer--which is more than we can say about some of the groups and organizations Komen has gladly gone to bed with in the past.

Postscript

Latest count: 40,228,818. Up over 70,000 in 30 minutes.

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap